[go: up one dir, main page]

DE69938187D1 - Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen - Google Patents

Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen

Info

Publication number
DE69938187D1
DE69938187D1 DE69938187T DE69938187T DE69938187D1 DE 69938187 D1 DE69938187 D1 DE 69938187D1 DE 69938187 T DE69938187 T DE 69938187T DE 69938187 T DE69938187 T DE 69938187T DE 69938187 D1 DE69938187 D1 DE 69938187D1
Authority
DE
Germany
Prior art keywords
cancer
ykl
prognosis
marker
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69938187T
Other languages
English (en)
Inventor
Paul A Price
Julia S Johansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of DE69938187D1 publication Critical patent/DE69938187D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
DE69938187T 1998-10-01 1999-09-29 Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen Expired - Lifetime DE69938187D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/164,862 US7229770B1 (en) 1998-10-01 1998-10-01 YKL-40 as a marker and prognostic indicator for cancers
PCT/US1999/022615 WO2000019206A1 (en) 1998-10-01 1999-09-29 Ykl-40 as a marker and prognostic indicator for cancers

Publications (1)

Publication Number Publication Date
DE69938187D1 true DE69938187D1 (de) 2008-04-03

Family

ID=22596399

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69938187T Expired - Lifetime DE69938187D1 (de) 1998-10-01 1999-09-29 Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen

Country Status (8)

Country Link
US (2) US7229770B1 (de)
EP (2) EP1804062A3 (de)
JP (1) JP2002525632A (de)
AT (1) ATE386938T1 (de)
AU (1) AU6275799A (de)
CA (1) CA2343972A1 (de)
DE (1) DE69938187D1 (de)
WO (1) WO2000019206A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034469A1 (en) * 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
AU2002319680B2 (en) * 2001-07-24 2008-04-10 Yale University Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
US20070269831A1 (en) * 2003-09-10 2007-11-22 Sloan-Kettering Institute For Cancer Research Method for Early Detection of Ovarian Cancer
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
US20050287544A1 (en) * 2003-12-01 2005-12-29 Francois Bertucci Gene expression profiling of colon cancer with DNA arrays
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
JP5087925B2 (ja) * 2004-12-07 2012-12-05 東レ株式会社 新規癌抗原ペプチド及びその用途
US20100196509A1 (en) * 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
ES2358917T3 (es) 2005-02-28 2011-05-16 Bio-Y A/S Anticuerpo nonoclonal ykl-40.
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
US8409411B2 (en) * 2005-12-02 2013-04-02 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Portland State University Nano-porous membrane based sensors
EP3913375A1 (de) 2006-01-11 2021-11-24 Bio-Rad Laboratories, Inc. Mikrofluidische vorrichtungen und verfahren zur verwendung bei der bildung und steuerung von nanoreaktoren
CN101437962A (zh) * 2006-03-03 2009-05-20 维里德克斯有限责任公司 预测杜克氏b结肠癌复发的分子检测
US20110143380A1 (en) * 2006-03-14 2011-06-16 The Washington University Alzheimer's disease biomarkers and methods of use
EP2530167A1 (de) 2006-05-11 2012-12-05 Raindance Technologies, Inc. Mikrofluidische Vorrichtungen
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2077912B1 (de) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorkohlenstoffemulsionsstabilisierende tenside
FR2908654B1 (fr) * 2006-11-20 2014-04-04 Oreal Utilisation cosmetique de proteines de type chitinase
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
CA2740028A1 (en) * 2008-01-23 2009-07-30 Herlev Hospital Ykl-40 as a general marker for non-specific disease
US20110070601A1 (en) * 2008-01-23 2011-03-24 Rigshospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP2315629B1 (de) 2008-07-18 2021-12-15 Bio-Rad Laboratories, Inc. Tröpfchenbibliotheken
AU2009291312A1 (en) * 2008-09-15 2010-03-18 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
WO2010028656A1 (en) * 2008-09-15 2010-03-18 Herlev Hospital, Region Hovedstaden Methods for classifying the severity of diseases or disorders
JP2012502284A (ja) * 2008-09-15 2012-01-26 ヘルレフ ホスピタル 疾患の処置及び監視の選択用マーカーとしてのｙｋｌ−４０
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
JP5911805B2 (ja) 2009-11-20 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ）
US8198035B2 (en) 2009-11-25 2012-06-12 Siemens Healthcare Diagnostics Inc. Galactose-α-1,3-galactose-macromolecule conjugates and methods employing same
EP2517025B1 (de) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Verfahren zur reduzierung des austauschs von molekülen zwischen tröpfchen
EP4484577A3 (de) 2010-02-12 2025-03-26 Bio-Rad Laboratories, Inc. Digitale analytanalyse
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
EP3859011A1 (de) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Verfahren zur bildung gemischter tröpfchen
EP3736281A1 (de) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
EP2694974B1 (de) * 2011-04-04 2015-10-21 Universiteit Gent Marker für akute nierenläsion
US20130035290A1 (en) * 2011-05-17 2013-02-07 Yale University Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
DE202012013668U1 (de) 2011-06-02 2019-04-18 Raindance Technologies, Inc. Enzymquantifizierung
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US9575073B2 (en) * 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
EP3524693A1 (de) 2012-04-30 2019-08-14 Raindance Technologies, Inc. Digitale analytanalyse
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
GB2545361B (en) 2015-04-10 2018-01-24 Applied Proteomics Inc Methods of assessing colorectal cancer status
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
RU2623869C1 (ru) * 2016-07-29 2017-06-29 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский государственный университет" (ТГУ, НИ ТГУ) Способ прогнозирования безрецидивной выживаемости у больных раком молочной железы
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
US20200292548A1 (en) * 2019-02-06 2020-09-17 Berg Llc Markers for the diagnosis of biochemical recurrence in prostate cancer
JP7356625B2 (ja) * 2019-07-08 2023-10-05 国立大学法人大阪大学 癌患者の予後予測方法、抗癌療法の有効性の予測方法および癌患者に対する適切な療法の選択方法
KR102142499B1 (ko) 2019-09-11 2020-08-10 재단법인 오송첨단의료산업진흥재단 Ykl-40 표적 인간 단일클론항체
EP4252243A2 (de) 2020-11-30 2023-10-04 Enigma Biointelligence, Inc. Nichtinvasive beurteilung von morbus alzheimer
CN114569725B (zh) * 2022-03-29 2023-05-12 潍坊医学院 Ykl-40在黑色素瘤治疗中的应用
KR20230157812A (ko) 2022-05-10 2023-11-17 재단법인 오송첨단의료산업진흥재단 항-키티나제-3-유사 단백질 1 항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628027A (en) 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US4828981A (en) * 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
JPS6323898A (ja) 1986-07-16 1988-02-01 Dainippon Pharmaceut Co Ltd 新規ポリペプチド及びそれをコ−ドするｄｎａ並びにそれらの製法
US5427954A (en) 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
US5773259A (en) 1996-03-20 1998-06-30 Smithkline Beecham Corporation Tissue remodeling proteins
EP0805206A3 (de) 1996-05-03 1999-09-15 Smithkline Beecham Corporation Menschliches Glycoprotein aus Knorpel
US5811535A (en) * 1996-08-09 1998-09-22 Smithkline Beecham Corporation Human cartilege gp39-like gene
AU6693996A (en) 1996-08-09 1998-03-06 Human Genome Sciences, Inc. Human chitinase alpha and chitinase alpha-2
US5726061A (en) * 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
ES2358917T3 (es) 2005-02-28 2011-05-16 Bio-Y A/S Anticuerpo nonoclonal ykl-40.

Also Published As

Publication number Publication date
JP2002525632A (ja) 2002-08-13
US7670599B2 (en) 2010-03-02
AU6275799A (en) 2000-04-17
WO2000019206A9 (en) 2000-09-08
EP1804062A3 (de) 2007-07-11
CA2343972A1 (en) 2000-04-06
US7229770B1 (en) 2007-06-12
EP1112497A1 (de) 2001-07-04
EP1112497B1 (de) 2008-02-20
WO2000019206A1 (en) 2000-04-06
EP1804062A2 (de) 2007-07-04
US20050226884A1 (en) 2005-10-13
ATE386938T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
DE69938187D1 (de) Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen
DE69930666D1 (de) Krebsnachweisverfahren und reagenzien
CY1112525T1 (el) Βελτιωμενες μεθοδοι βεαμινg
ATE352641T1 (de) Zirkulierendes epstein-barr virus dna im serum der patienten mit gastrischem krebs
ATE331811T1 (de) Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
ATE337011T1 (de) Modifizierte psma-liganden und deren verwendung
ATE337413T1 (de) Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen
WO2006128192A3 (en) Use of free circulating dna for diagnosis, prognosis, and treatment of cancer
WO2002057787A3 (en) Detection of survivin in the biological fluids of cancer patients
ATE354588T1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
DE69929785D1 (de) Verfahren zur Diagnose, Erkennung, und Einstufung von Dickdarmkrebs
ATE416674T1 (de) Nachweis von verunreinigungen mittels selbstständiger einheiten die zielmaterialbindende farbstoffe gebrauchen
ATE531820T1 (de) Gesundheitszustandstest
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2004112570A3 (en) Detection of survivin in the biological fluids of cancer patients
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
CY1105025T1 (el) Αναλυση λεπτινης βασιζομενη στην ανιχνευση εκφρασης ang-2
ATE534905T1 (de) Cop1-moleküle und verwendungen davon
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
ATE321886T1 (de) Oligonukleotide und diese enthaltende komplexe zur detektion der anwesenheit oder abwesenheit einer zielnukleinsäure in einer probe
WO2002064015A3 (en) Pin1 as a marker for prostate cancer
BR0314155A (pt) Métodos para diagnosticar câncer cervical
DK2199801T3 (da) Biomarkører til tidlig påvisning af ovariecancer
ATE377192T1 (de) Diagnostisches verfahren für eierstock- und endometriumtumore basierend auf dem nachweis des l1-adhäsionsmoleküls

Legal Events

Date Code Title Description
8332 No legal effect for de